✣OncoGonFROM DISCOVERY TO IMPACT
HomeAssetsTriage & Prioritisation
3D Tumour IntelligenceExperimentsImagingSegmentation & QCResponse AnalysisAI Analysis (OSIEL)
Qualified AssetsIndustry & Data RoomCollaborationReports & Insights
Admin
HomeReports & Insights
PORTFOLIO ANALYTICS · ILLUSTRATIVE

Reports & Insights

Explore portfolio performance, scientific operations, governance status, and commercialisation progress across OncoGon.

Illustrative portfolio metrics from current portfolio data. Current scope: Last 30 days · all research contexts. Matching category charts and study comparisons update; aggregate KPI totals remain illustrative portfolio baselines.
Total Assets245Portfolio
Active Experiments18Execution
Qualified Assets36Human decision
Active Studies183D models
Evidence Items32Linked evidence
Industry Engagements12TTO
245Discovery72Triage48Validation28Scientific Review36Qualification12TTO12Industry

Assets by Cancer Type

Open source
Breast Cancer: 78Lung Cancer: 52Glioblastoma: 39Melanoma: 31Other: 45

Assets by Stage

Open source
Discovery: 43Screening: 723D Study: 48Review: 28Qualified: 36Partner-Ready: 18

Assets by Modality

Open source
Small Molecule: 93Biologic: 62Antibody: 44PROTAC: 20Other: 26

Assets by Owner

Open source
S. Mokoena: 67J. Patel: 54L. Chen: 49M. Rossi: 42A. Kumar: 33

Portfolio Observations

Independent review gates concentrate the qualification backlogIllustrative portfolio observation from the qualification workflow.
Explore
Three active studies require QC follow-upIllustrative operations view; inspect the QC review queue for details.
Explore
Breast-cancer assets form the largest validation groupIllustrative distribution of active portfolio assets.
Explore